



## Resource

# The Federal Preventive Services Benefit Mandate and Related California Mandates

February 2, 2022

Prepared by  
**California Health Benefits Review Program**

[www.chbrp.org](http://www.chbrp.org)

Suggested Citation: *California Health Benefits Review Program (CHBRP). (2022). Resource: The Federal Preventive Services Benefit Mandate and Related California Mandates. Berkeley, CA*

## THE FEDERAL PREVENTIVE SERVICES BENEFIT MANDATE AND RELATED CALIFORNIA MANDATES

As a tool for analyzing legislation, the California Health Benefits Review Program (CHBRP) maintains this resource to identify potential overlap between the federal benefit mandate requiring health insurance coverage of some preventive services and California state benefit mandates. CHBRP provides independent evidence-based analysis of health insurance benefits-related legislation at the request of the California Legislature.

As indicated in federal<sup>1</sup> and California state<sup>2</sup> law, non-grandfathered group and individual health insurance plans and policies must cover certain preventive services *without cost-sharing when delivered by in-network providers*. As well as prohibiting copayments and coinsurance, application of deductibles (another form of cost-sharing) is also prohibited.<sup>3</sup> Preventive services recommended in any of the following are required to be covered without cost sharing as soon as 12 months after a recommendation appears:

- The United States Preventive Services Task Force (USPSTF) A and B recommendations<sup>4</sup>
- The Health Resources and Services Administration (HRSA)-supported health plan coverage guidelines for women’s preventive services<sup>5</sup>
- The HRSA-supported comprehensive guidelines for infants, children, and adolescents, which include:
  - The *Bright Futures* Recommendations for Pediatric Preventive Health Care<sup>6</sup>, and
  - The recommendations of the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children<sup>7</sup>
- The Advisory Committee on Immunization Practices (ACIP) recommendations that have been adopted by the Director of the Centers for Disease Control and Prevention (CDC)<sup>8</sup>

This resource is arranged as follows:

| <u>Tables</u>  | <u>Page</u> |
|--|-------------|
| <b>Table 1.</b> Federal Health Insurance Benefit Mandates as Defined by Reference to USPSTF A and B Recommendations & Related Mandates in California State Law   | 4           |
| <b>Table 2.</b> Federal Health Insurance Benefit Mandates as Defined by Reference to HRSA-Supported Health Plan Coverage Guidelines for Women’s Preventive Services & Related Mandates in California State Law | 32          |

<sup>1</sup> Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act.

<sup>2</sup> California Health and Safety Code 1367.002 and California Insurance Code Section 10112.2.

<sup>3</sup> The deductible prohibition is specified at: <https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/preventive-care-background>.

<sup>4</sup> USPSTF created a concise document summarizing its A and B recommendations (Current as of January 2021), available at: <https://www.uspreventiveservicestaskforce.org/Page/Name/uspstf-a-and-b-recommendations/>. However, for this resource CHBRP consulted USPSTF’s A-Z Topic Guide because up-to-date summaries of recommendations are available through links on that webpage: <https://www.uspreventiveservicestaskforce.org/BrowseRec/Index>.

<sup>5</sup> Available at: <https://www.hrsa.gov/womens-guidelines/index.html>.

<sup>6</sup> Available at: <https://brightfutures.aap.org/materials-and-tools/tool-and-resource-kit/Pages/default.aspx>.

<sup>7</sup> Available at: <https://www.hrsa.gov/advisory-committees/heritable-disorders/recommendations-reports/index.html>.

<sup>8</sup> “Recommended immunization schedules for children and adolescents aged 18 years or younger—United States, 2020” available at: <https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf>. “Recommended immunization schedule for adults aged 19 years or older—United States, 2020” available at: <https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf>.

|  |    |
|--|----|
| <b>Table 3.</b> Federal Health Insurance Benefit Mandates as Specified by Reference to HRSA-Supported Comprehensive Guidelines for Infants, Children, and Adolescents & Related Mandates in California State Law | 38 |
| <b>Table 4.</b> Federal Health Insurance Benefit Mandates as Specified by ACIP Recommendations   | 40 |

## Methods

For Table 1, CHBRP reviewed known benefit mandates in California’s Health and Safety Code (H&SC) and the California Insurance Code (IC)<sup>9</sup> to identify state benefit mandates that seemed to overlap with the tests, treatments, or services partially or fully addressed by one or more of USPSTF’s recommendations. Where there appears to be overlap, the relevant H&SC and IC are listed in the last column. If there does not appear to be overlap, “None identified” appears in the last column. CHBRP defines benefit mandates as per its authorizing statute.<sup>10</sup> Therefore, the listed mandates fall into one or more of the following categories: (a) offer or provide coverage for the screening, diagnosis, or treatment of specific diseases or conditions; (b) offer or provide coverage for types of health care treatments or services, including coverage of medical equipment, supplies, or drugs used in a treatment or service; and/or (c) offer or provide coverage permitting treatment or services from a specific type of health care provider. Listed mandates also include those that (d) specify terms (limits, timeframes, copayments, deductibles, coinsurance, etc.) for any of the other categories.

USPSTF created a concise document summarizing its A and B recommendations<sup>11</sup> (last updated in December 2021). Table 1 is organized categorically by condition or disease groups addressed by a USPSTF recommendation. Categories are identified as cancer, chronic conditions, health promotion, pregnancy-related, and sexual health. The columns in Table 1 also indicate the specified test, treatment, or service, and any specified sex, age, or other characteristics of eligible enrollees. Blanks in these columns indicate that the USPSTF recommendation was not specific. It should be noted that USPSTF often does not specify age groups, but rather makes recommendations for “children,” “adolescents,” or “adults.” The next column identifies specified terms of coverage. For clarity, the terms specified by the federal preventive services benefit mandate are always included and are in italics; the terms are “without cost-sharing when in-network” and “as soon as 12 months after recommendation release.” If the USPSTF recommendation was released less than 12 months ago, that row is highlighted in the table. When the USPSTF recommendation seems to imply stipulations (e.g., frequency of event) that could affect the terms of benefit coverage, these are listed in the same column, without italics. When updates are made to any of the schedules, new benefit mandates are listed individually and highlighted, in order to indicate which are less than 12 months old and therefore may not be among the list for which benefit coverage is required.

For Table 2, CHBRP used complimentary methods, except that the known benefit mandates in the H&SC and IC were reviewed to identify overlap with HRSA-supported health plan coverage guidelines for women’s preventive services,<sup>12</sup> developed by the Institute of Medicine (IOM)<sup>13</sup> in 2011 and updated by the Women’s Preventive Services Initiative<sup>14</sup> in 2019.

For Table 3 and Table 4, CHBRP used complimentary methods with a few exceptions. For Table 3, the known benefit mandates in the H&SC and IC were reviewed to identify overlap with HRSA-supported

<sup>9</sup> CHBRP maintains a list of benefit mandates current in California, available at:

[http://www.chbrp.org/other\\_publications/index.php](http://www.chbrp.org/other_publications/index.php).

<sup>10</sup> Available at: <http://www.chbrp.org/faqs.php>.

<sup>11</sup> Available at: <https://www.uspreventiveservicestaskforce.org/Page/Name/uspstf-a-and-b-recommendations/>.

<sup>12</sup> Available at: <https://www.hrsa.gov/womens-guidelines/index.html>.

<sup>13</sup> The Institute of Medicine (IOM) is now known as the National Academy of Medicine (NAM).

<sup>14</sup> More information about the Women’s Preventive Services Initiative can be found at:

<http://www.womenspreventivehealth.org/>.

comprehensive guidelines for infants, children, and adolescents, which include: (1) The *Bright Futures* Recommendations for Pediatric Preventive Health Care;<sup>15</sup> and (2) the recommendations of the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children.<sup>16</sup> For Table 4, the known benefit mandates in the H&SC and IC were reviewed to identify overlap with ACIP recommendations that have been adopted by the Director of the CDC.<sup>17</sup> For both Table 3 and Table 4, CHBRP has not listed each federal health insurance benefit mandate as specified by reference to HRSA and ACIP. Because individual recommendations often relate to multiple conditions and diseases, and because the schedules often imply complex variation by age—and sometimes by sex—we have aggregated the benefit mandates as screenings or treatments related to “wellness” or as “vaccine preventable diseases.” Links to HRSA- and ACIP-supported schedules are provided in the tables.

---

<sup>15</sup> Available at: <https://brightfutures.aap.org/materials-and-tools/tool-and-resource-kit/Pages/default.aspx>.

<sup>16</sup> Available at: <https://www.hrsa.gov/advisory-committees/heritable-disorders/recommendations-reports/index.html>.

<sup>17</sup> “Recommended immunization schedules for children and adolescents aged 18 years or younger—United States, 2020” available at: <https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf>. “Recommended immunization schedule for adults aged 19 years or older—United States, 2020” available at: <https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf>.

**Table 1. Federal Health Insurance Benefit Mandates as Specified by Reference to USPSTF A and B Recommendations<sup>18</sup> & Related Mandates in California State Law<sup>19,20</sup>**

| #  | Federal Mandates as Specified by Reference to USPSTF |  |   |                                   |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>  |
|--|--|--|---|-----------------------------------|---|---|--|
|  | Condition or Disease                                 | Test, Treatment, or Service  | Specified Sex/Other <sup>23</sup>   | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>   |   |  |
| In the rows that follow, recommendations released less than 12 months prior to 2/2/2022 are highlighted in the same color as this cell. If the new recommendation revises an older recommendation, the change is <u>underlined and defined</u> . |  |  |   |                                   |   |   |  |
| <b>Cancer</b>  |  |  |   |                                   |   |   |  |
| 1  | Breast cancer  | An appropriate brief familial risk assessment tool. Women with a positive result should receive genetic counseling followed by genetic testing for BRCA1 or BRCA2, if indicated. | Women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or an ancestry associated with <i>BRCA1</i> or <i>BRCA2</i> gene mutation |                                   | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i><br><br>Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing | BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/brc-a-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/brc-a-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing</a><br><br>(August 2019)<br><br>Grade: B | Breast cancer screening, diagnosis, and treatment:<br>H&SC 1367.6<br>IC 10123.8<br>Cancer screening tests:<br>H&SC 1367.665<br>IC 10123.20 |

<sup>18</sup> Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act.

<sup>19</sup> For brevity, CHBRP has not listed in each row the California mandate (H&SC 1367.002 & IC 10112.2) that requires compliance with federal laws and regulations requiring coverage of preventive services without cost-sharing (Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act).

<sup>20</sup> CHBRP is aware that state regulation may also require benefit coverage, but is focusing this resource on health insurance benefit mandate laws.

<sup>21</sup> Unless otherwise noted, the links listed below were accessed on or before 2/2/2022.

<sup>22</sup> Unless otherwise noted, the mandates listed below were reviewed on or before 2/2/2022.

<sup>23</sup> "Other" is included here in order to specify pregnant or non-pregnant women.

<sup>24</sup> "Other" is included here when more details are available about the intended group, beyond age.

<sup>25</sup> *Italicized terms* are explicit in the federal law (Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act). Non-italicized terms of benefit coverage are implied by the referenced recommendation.



| # | Federal Mandates as Specified by Reference to USPSTF |  |  |   |  | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>   |
|---|--|--|--|---|--|---|---|
|   | Condition or Disease                                 | Test, Treatment, or Service  | Specified Sex/Other <sup>23</sup>  | Specified Age/Other <sup>24</sup>   | Terms <sup>25</sup>  |   |   |
| 2 | Breast cancer  | Offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors | Women at increased risk for breast cancer and at low risk for adverse medication effects |   | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i>                      | Breast Cancer: Medication Use to Reduce Risk<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction</a><br><br>(September 2019)<br><br>Grade: B | Breast cancer screening, diagnosis, and treatment:<br><br>H&SC 1367.6<br><br>IC 10123.8<br><br>Cancer screening tests:<br><br>H&SC 1367.665<br><br>IC 10123.20  |
| 3 | Breast Cancer  | Screening mammography  | Women  | 50 to 74 years<br><br>Note: HRSA (see Table 2, below) recommends beginning at age 40, so the Preventive Services mandate prohibits cost sharing for women aged 40-74. | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i><br><br>Biennial      | Breast Cancer: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening</a><br><br>(January 2016)<br><br>Grade: B   | Mammography:<br><br>H&SC 1367.65<br><br>IC 10123.81<br><br>Breast cancer screening, diagnosis, and treatment:<br><br>H&SC 1367.6<br><br>IC 10123.8<br><br>Cancer screening tests:<br><br>H&SC 1367.665<br><br>IC 10123.20 |
| 4 | Cervical cancer                                      | Cytology (Pap smear)   | Women  | 21 to 65 years*<br><br>*Women ages 30 to 65 have the option of this recommendation or the recommendation below  | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i><br><br>Every 3 years | Cervical Cancer: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening</a><br><br>(August 2018)<br><br>Grade: A  | Cancer screening tests:<br><br>H&SC 1367.665<br><br>IC 10123.20<br><br>Cervical cancer screening:<br><br>H&SC 1367.66<br><br>IC 10123.18  |

| # | Federal Mandates as Specified by Reference to USPSTF                |  |                                   |  |  | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>  |
|---|---|--|-----------------------------------|--|--|---|--|
|   | Condition or Disease  | Test, Treatment, or Service  | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>  | Terms <sup>25</sup>  |   |  |
| 5 | Cervical cancer   | Cytology and high-risk human papillomavirus (hrHPV) testing (cotesting) or hrHPV testing alone*<br><br>*The 2018 recommendation specifies cotesting or hrHPV alone (every 5 years) as an alternative to cytology alone every 3 years | Women                             | 30 to 65 who want to lengthen screening interval*<br><br>*Women have the option of this lengthened screening interval or the alternate recommendation above  | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i><br><br>Every 5 years | Cervical Cancer: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening</a><br><br>(August 2018)<br><br>Grade: A  | Cancer screening tests:<br><br>H&SC 1367.665<br><br>IC 10123.20<br><br>Cervical cancer screening:<br><br>H&SC 1367.66<br><br>IC 10123.18 |
| 6 | Colorectal Cancer<br><br>(Topic is in the process of being updated) | Aspirin  |                                   | 50 to 59 with a $\geq 10\%$ 10-year cardiovascular disease (CVD) risk, not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i>                      | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer</a><br><br>(April 2016)<br><br>Grade: B | None identified  |



| # | Federal Mandates as Specified by Reference to USPSTF |                             |                                   |                                   |   | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup> |
|---|--|-----------------------------|-----------------------------------|-----------------------------------|---|--|---|
|   | Condition or Disease                                 | Test, Treatment, or Service | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>   |  |   |
| 7 | Colorectal cancer (CRC)                              | Screening                   |                                   | 45 to 49 years                    | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Screening should begin at age 45 and continue until age 75. Frequency of screening is dependent upon the chosen method.<sup>26</sup></p> <p>The risks and benefits of these screenings may vary</p> | <p>Colorectal Cancer: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening</a></p> <p>(May 2021)</p> <p>Grade: B</p> | <p>Cancer screening tests:</p> <p>H&amp;SC 1367.665</p> <p>IC 10123.20</p>        |
| 8 | Colorectal cancer (CRC)                              | Screening                   |                                   | 50 to 75 years                    | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Screening should begin at age 45 and continue until age 75. Frequency of screening is dependent upon the chosen method.</p> <p>The risks and benefits of these screenings may vary</p>              | <p>Colorectal Cancer: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening</a></p> <p>(May 2021)</p> <p>Grade: A</p> | <p>Cancer screening tests:</p> <p>H&amp;SC 1367.665</p> <p>IC 10123.20</p>        |

<sup>26</sup> The frequency for tests is not mentioned in the Summary of Recommendations; however it is included in the Recommendation Statement available at: <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/colorectal-cancer-screening2#tab>.



| #  | Federal Mandates as Specified by Reference to USPSTF |  |   |   |  | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup> |
|----|--|--|---|---|--|--|---|
|    | Condition or Disease                                 | Test, Treatment, or Service  | Specified Sex/Other <sup>23</sup>   | Specified Age/Other <sup>24</sup>   | Terms <sup>25</sup>  |  |   |
| 9  | Lung cancer  | Screening with low-dose computed tomography  |   | Adults 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.</p> | <p>Lung Cancer: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening</a></p> <p>(March 2021)</p> <p>Grade: B</p>   | <p>Cancer screening tests:</p> <p>H&amp;SC 1367.665</p> <p>IC 10123.20</p>        |
| 10 | Ovarian, tubal, or peritoneal cancer                 | An appropriate brief familial risk assessment tool. Women with a positive result should receive genetic counseling followed by genetic testing for BRCA1 or BRCA2, if indicated. | Women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or an ancestry associated with BRCA1 or BRCA2 gene mutation |   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing</p>   | <p>BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/brc-a-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/brc-a-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing</a></p> <p>(August 2019)</p> <p>Grade: B</p> | <p>Cancer screening tests:</p> <p>H&amp;SC 1367.665</p> <p>IC 10123.20</p>        |



| #                         | Federal Mandates as Specified by Reference to USPSTF |  |                                   |  |   | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>  |
|---------------------------|--|--|-----------------------------------|--|---|--|--|
|                           | Condition or Disease                                 | Test, Treatment, or Service  | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>  | Terms <sup>25</sup>   |  |  |
| 11                        | Skin cancer  | Counseling about minimizing exposure to ultraviolet radiation to reduce risk for skin cancer |                                   | Persons aged 6 months to 24 years, including parents of young children, who have fair skin | Without cost-sharing when in-network<br><br>As soon as 12 months after recommendation release                 | Skin Cancer Prevention: Behavioral Counseling<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/skin-cancer-counseling">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/skin-cancer-counseling</a><br><br>(March 2018)<br><br>Grade: B   | Comprehensive preventive care for children aged 16 years or younger:<br><br>H&SC 1367.35<br>IC 10123.5<br><br>Comprehensive preventive care for children aged 17 and 18 years:<br><br>H&SC 1367.3<br>IC 10123.55 |
| <b>Chronic Conditions</b> |  |  |                                   |  |   |  |  |
| 12                        | Abdominal aortic aneurysm (AAA)                      | Ultrasonography  | Men                               | 65 to 75 who have ever smoked  | Without cost-sharing when in-network<br><br>As soon as 12 months after recommendation release<br><br>One-time | Abdominal Aortic Aneurysm: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/abdominal-aortic-aneurysm-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/abdominal-aortic-aneurysm-screening</a><br><br>(December 2019)<br><br>Grade: B                         | None identified  |
| 13                        | Prediabetes and Type 2 Diabetes                      | Screening  |                                   | 35 to 70 who have overweight or obesity  | Without cost-sharing when in-network<br><br>As soon as 12 months after recommendation release                 | Prediabetes and Type 2 Diabetes: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes</a><br><br>(August 2021)<br><br>Grade: B | None identified  |

| #  | Federal Mandates as Specified by Reference to USPSTF                           |  |                                   |   |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup> |
|----|--|--|-----------------------------------|---|---|---|---|
|    | Condition or Disease   | Test, Treatment, or Service  | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>   | Terms <sup>25</sup>   |   |   |
| 14 | Cardiovascular disease (CVD)<br><br>(Topic is in the process of being updated) | Aspirin  |                                   | 50 to 59 with a $\geq 10\%$ 10-year CVD risk, not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer</a><br><br>(April 2016)<br><br>Grade: B   | None identified   |
| 15 | Cardiovascular disease (CVD)   | Intensive behavioral interventions to promote a healthful diet and physical activity |                                   | Adults who are overweight or obese and have additional cardiovascular disease (CVD) risk factors  | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/healthy-diet-and-physical-activity-counseling-adults-with-high-risk-of-cvd">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/healthy-diet-and-physical-activity-counseling-adults-with-high-risk-of-cvd</a><br><br>(November 2020)<br><br>Grade: B | None identified   |



| #  | Federal Mandates as Specified by Reference to USPSTF                       |   |                                   |  |  | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>   |
|----|--|---|-----------------------------------|--|--|---|---|
|    | Condition or Disease   | Test, Treatment, or Service                   | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>  | Terms <sup>25</sup>  |   |   |
| 16 | Cardiovascular disease (CVD)<br>(Topic is in the process of being updated) | Statin  |                                   | 40 to 75 with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of ≥10% | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Low- to moderate-dose statin</p> <p>Requires universal lipids screening.</p>                               | <p>Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication</a></p> <p>(November 2016)</p> <p>Grade: B</p> | None identified   |
| 17 | Depression<br>(Topic is in the process of being updated)                   | Screening for major depressive disorder (MDD) |                                   | 12 to 18 years   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>When systems are in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up</p> | <p>Depression in Children and Adolescents: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/depression-in-children-and-adolescents-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/depression-in-children-and-adolescents-screening</a></p> <p>(February 2016)</p> <p>Grade: B</p>                                    | <p>Comprehensive preventive care for children aged 16 years or younger:</p> <p>H&amp;SC 1367.35</p> <p>IC 10123.5</p> <p>Comprehensive preventive care for children aged 17 and 18 years:</p> <p>H&amp;SC 1367.3</p> <p>IC 10123.55</p> |

| #  | Federal Mandates as Specified by Reference to USPSTF     |                             |  |                                   |  | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup> |
|----|--|-----------------------------|--|-----------------------------------|--|--|---|
|    | Condition or Disease                                     | Test, Treatment, or Service | Specified Sex/Other <sup>23</sup>      | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>  |  |   |
| 18 | Depression<br>(Topic is in the process of being updated) | Screening                   | Includes pregnant and postpartum women | Adults                            | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>When staff-assisted depression care supports are in place to assure accurate diagnosis, effective treatment, and appropriate follow-up</p> | <p>Depression in Adults: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/depression-in-adults-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/depression-in-adults-screening</a></p> <p>(January 2016)</p> <p>Grade: B</p>                                    | <p>Maternal mental health:</p> <p>H&amp;SC 1367.625</p> <p>IC 10123.867</p>       |
| 19 | Hepatitis B virus (HBV) infection                        | Screening                   | Persons at high risk for infection     | Adolescents and adults            | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p>   | <p>Hepatitis B Virus Infection: Screening, 2020</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-b-virus-infection-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-b-virus-infection-screening</a></p> <p>(December 2020)</p> <p>Grade: B</p>        | None identified   |
| 20 | Hepatitis C virus (HCV) infection                        | Screening                   |  | 18 to 79 years                    | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p>   | <p>Hepatitis C Virus Infection in Adolescents and Adults: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-c-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-c-screening</a></p> <p>(March 2020)</p> <p>Grade: B</p> | None identified   |



| #  | Federal Mandates as Specified by Reference to USPSTF                            |  |                                   |   |  | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>                                 |
|----|---|--|-----------------------------------|---|--|--|---|
|    | Condition or Disease  | Test, Treatment, or Service                        | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>                   | Terms <sup>25</sup>  |  |   |
| 21 | Hypertension  | Office blood pressure measurement (OBPM)           |                                   | 18 and older  | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Obtain measurements outside of clinical setting for diagnostic confirmation</p> <p>Adults 18 to 39 with normal blood pressure who do not have other risk factors should be screened every 3 to 5 years</p> <p>Adults ages 40 and older and those at increased risk should be screened annually</p> | <p>Hypertension in Adults: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hypertension-in-adults-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hypertension-in-adults-screening</a></p> <p>(April 2021)</p> <p>Grade: A</p>  | <p>Comprehensive preventive care for children aged 17 and 18 years:</p> <p>H&amp;SC 1367.3</p> <p>IC 10123.55</p> |
| 22 | Latent Tuberculosis Infection<br><br>(Topic is in the process of being updated) | Screening for latent tuberculosis infection (LTBI) |                                   | Asymptomatic adults at increased risk for infection | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p>   | <p>Latent Tuberculosis Infection: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/latent-tuberculosis-infection-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/latent-tuberculosis-infection-screening</a></p> <p>(September 2016)</p> <p>Grade: B</p> | None identified   |

| #  | Federal Mandates as Specified by Reference to USPSTF       |   |                                   |   |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>                          |
|----|--|---|-----------------------------------|---|---|---|--|
|    | Condition or Disease                                       | Test, Treatment, or Service   | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>   | Terms <sup>25</sup>   |   |  |
| 23 | Obesity  | Screening and comprehensive, intensive behavioral interventions to promote improvement in weight status |                                   | Children and adolescents age 6 years and older <sup>27</sup>  | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Obesity in Children and Adolescents: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-children-and-adolescents-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-children-and-adolescents-screening</a><br><br>(June 2017)<br><br>Grade: B                              | Comprehensive preventive care for children aged 16 years or younger:<br><br>H&SC 1367.35<br><br>IC 10123.5 |
| 24 | Obesity  | Intensive, multicomponent behavioral interventions  |                                   | Adults with body mass index (BMI) of 30 kg/m <sup>2</sup> or higher   | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions</a><br><br>(September 2018)<br><br>Grade: B | None identified  |
| 25 | Osteoporosis<br>(Topic is in the process of being updated) | Screening   | Women                             | Postmenopausal women younger than 65 who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Osteoporosis to Prevent Fractures: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening</a><br><br>(June 2018)<br><br>Grade: B  | Osteoporosis:<br><br>H&SC 1367.67<br><br>IC 10123.185  |

<sup>27</sup> The Summary Recommendation does not define obesity. Obesity is defined in the Recommendation Statement “as having a BMI at >95th percentile for age and gender”, but the recommendation is not explicitly restricted to obese children and adolescents. The Recommendation Statement is available at: <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/obesity-in-children-and-adolescents-screening1>.

| #                       | Federal Mandates as Specified by Reference to USPSTF       |  |                                   |   |   | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>   |
|-------------------------|--|--|-----------------------------------|---|---|--|---|
|                         | Condition or Disease                                       | Test, Treatment, or Service  | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>                   | Terms <sup>25</sup>   |  |   |
| 26                      | Osteoporosis<br>(Topic is in the process of being updated) | Screening  | Women                             | 65 and older  | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Osteoporosis to Prevent Fractures: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening</a><br><br>(June 2018)<br><br>Grade: B   | Osteoporosis:<br>H&SC 1367.67<br><br>IC 10123.185   |
| <b>Health Promotion</b> |  |  |                                   |   |   |  |   |
| 27                      | Alcohol misuse   | Screening and Brief behavioral counseling interventions to reduce unhealthy alcohol use for persons engaged in risky or hazardous drinking |                                   | Adults 18 years or older, including pregnant women. | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions</a><br><br>(November 2018)<br><br>Grade: B | Alcoholism treatment:<br>H&SC 1367.2(a)<br><br>IC 10123.6<br><br>Nicotine or chemical dependency treatment in licensed alcoholism or chemical dependency facilities:<br>H&SC 1367.2(b)<br><br>IC 10123.6<br><br>Maternity services:<br>IC 10123.865<br><br>IC 10123.866 |





| #  | Federal Mandates as Specified by Reference to USPSTF |                               |                                   |   |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>                          |
|----|--|-------------------------------|-----------------------------------|---|---|---|--|
|    | Condition or Disease                                 | Test, Treatment, or Service   | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>   | Terms <sup>25</sup>   |   |  |
| 28 | Dental caries  | Oral fluoride supplementation |                                   | 6 months of age through 5 years whose primary water source is deficient in fluoride |   | Prevention of Dental Caries in Children Younger Than 5 Years: Screening and Interventions<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-dental-caries-in-children-younger-than-age-5-years-screening-and-interventions1">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-dental-caries-in-children-younger-than-age-5-years-screening-and-interventions1</a><br><br>(December 2021)<br><br>Grade: B | Comprehensive preventive care for children aged 16 years or younger:<br><br>H&SC 1367.35<br><br>IC 10123.5 |
| 29 | Dental caries  | Fluoride varnish              |                                   | Age of primary tooth eruption through 5 years                                       | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Prevention of Dental Caries in Children Younger Than 5 Years: Screening and Interventions<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-dental-caries-in-children-younger-than-age-5-years-screening-and-interventions1">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-dental-caries-in-children-younger-than-age-5-years-screening-and-interventions1</a><br><br>(December 2021)<br><br>Grade: B | Comprehensive preventive care for children aged 16 years or younger:<br><br>H&SC 1367.35<br><br>IC 10123.5 |



| #  | Federal Mandates as Specified by Reference to USPSTF |  |                                   |   |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>   |
|----|--|--|-----------------------------------|---|---|---|---|
|    | Condition or Disease                                 | Test, Treatment, or Service            | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>                                       | Terms <sup>25</sup>   |   |   |
| 30 | Falls  | Exercise interventions                 |                                   | 65 and older who are community-dwelling and at increased risk for falls | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Falls Prevention in Community-Dwelling Older Adults: Interventions<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/falls-prevention-in-older-adults-interventions">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/falls-prevention-in-older-adults-interventions</a><br><br>(April 2018)<br><br>Grade: B   | None identified   |
| 31 | Gonococcal ophthalmia neonatorum                     | Prophylactic ocular topical medication |                                   | Newborns  | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: Preventive Medication<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/ocular-prophylaxis-for-gonococcal-ophthalmia-neonatorum-preventive-medication">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/ocular-prophylaxis-for-gonococcal-ophthalmia-neonatorum-preventive-medication</a><br><br>(January 2019)<br><br>Grade: A | Maternity services:<br>IC 10123.865<br>IC 10123.866<br><br>Comprehensive preventive care for children aged 16 years or younger:<br>H&SC 1367.35<br>IC 10123.5 |

| #  | Federal Mandates as Specified by Reference to USPSTF |   |                                   |  |   | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup> |
|----|--|---|-----------------------------------|--|---|--|---|
|    | Condition or Disease                                 | Test, Treatment, or Service   | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>  | Terms <sup>25</sup>   |  |   |
| 32 | Intimate Partner Violence                            | Screening for intimate partner violence<br><br>Provide or refer women who screen positive to ongoing support services*<br><br>*The 2018 recommendation references ongoing support services as compared to the previous support services | Women of reproductive age         |  | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-screening</a><br><br>(October 2018)<br><br>Grade: B   | None identified   |
| 33 | Tobacco use  | Interventions including education or brief counseling to prevent initiation of tobacco use  |                                   | School-aged children and adolescents who have not started to use tobacco | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Prevention and Cessation of Tobacco Use in Children and Adolescents: Primary Care Interventions<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/tobacco-and-nicotine-use-prevention-in-children-and-adolescents-primary-care-interventions">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/tobacco-and-nicotine-use-prevention-in-children-and-adolescents-primary-care-interventions</a><br><br>(April 2020)<br><br>Grade: B | None identified   |



| #  | Federal Mandates as Specified by Reference to USPSTF |  |                                   |                                   |  | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup> |
|----|--|--|-----------------------------------|-----------------------------------|--|---|---|
|    | Condition or Disease                                 | Test, Treatment, or Service  | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>  |   |   |
| 34 | Tobacco use  | Ask about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and/or FDA-approved pharmacotherapy for cessation |                                   | Adults who are not pregnant       | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> | <p>Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions</a></p> <p>(January 2021)</p> <p>Grade: A</p> | None identified   |



| #  | Federal Mandates as Specified by Reference to USPSTF |   |                                   |                                   |   | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>                                     |
|----|--|---|-----------------------------------|-----------------------------------|---|--|---|
|    | Condition or Disease                                 | Test, Treatment, or Service                         | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>   |  |   |
| 35 | Visual impairment                                    | Vision screening for amblyopia and its risk factors |                                   | Children aged 3-5 years           | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>At least once</p>   | <p>Vision in Children Ages 6 months to 5 Years: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/vision-in-children-ages-6-months-to-5-years-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/vision-in-children-ages-6-months-to-5-years-screening</a></p> <p>(September 2017)</p> <p>Grade: B</p> | <p>Comprehensive preventive care for children aged 16 years or younger:</p> <p>H&amp;SC 1367.35</p> <p>IC 10123.5</p> |
| 36 | Drug misuse  | Ask about drug use                                  |                                   | 18 years or older                 | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>When services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred.</p> | <p>Unhealthy Drug Use: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/drug-use-illicit-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/drug-use-illicit-screening</a></p> <p>(June 2020)</p> <p>Grade: B</p>   | None identified   |

| #                        | Federal Mandates as Specified by Reference to USPSTF |  |                                       |                                   |  | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>   |
|--------------------------|--|--|---------------------------------------|-----------------------------------|--|--|---|
|                          | Condition or Disease                                 | Test, Treatment, or Service  | Specified Sex/Other <sup>23</sup>     | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>  |  |   |
| <b>Pregnancy Related</b> |  |  |                                       |                                   |  |  |   |
| 37                       | Alcohol misuse                                       | Screening and brief behavioral counseling interventions to reduce unhealthy alcohol use for persons engaged in risky or hazardous drinking | Pregnant women                        | 18 years or older                 | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i>  | Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions</a><br><br>(November 2018)<br><br>Grade: B | Alcoholism treatment:<br>H&SC 1367.2(a)<br>IC 10123.6<br><br>Nicotine or chemical dependency treatment in licensed alcoholism or chemical dependency facilities:<br>H&SC 1367.2(b)<br>IC 10123.6<br><br>Maternity services:<br>IC 10123.865<br>IC 10123.866 |
| 38                       | Bacteriuria  | Urine culture  | Pregnant persons who are asymptomatic |                                   | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i><br><br>At 12 to 16 weeks' gestation or at the first prenatal visit, if later | Asymptomatic Bacteriuria in Adults: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspsstf/recommendation/asymptomatic-bacteriuria-in-adults-screening">https://www.uspreventiveservicestaskforce.org/uspsstf/recommendation/asymptomatic-bacteriuria-in-adults-screening</a><br><br>(September 2019)<br><br>Grade: B   | Maternity services:<br>IC 10123.865<br>IC 10123.866   |



| #  | Federal Mandates as Specified by Reference to USPSTF |  |   |                                   |  | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>  |
|----|--|--|---|-----------------------------------|--|---|--|
|    | Condition or Disease                                 | Test, Treatment, or Service                            | Specified Sex/Other <sup>23</sup>   | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>  |   |  |
| 39 | Breastfeeding  | Interventions to support breastfeeding                 | Pregnant women, new mothers, and their children                                   |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>During pregnancy and after birth</p> | <p>Breastfeeding: Primary Care Interventions</p> <p><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breastfeeding-primary-care-interventions">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breastfeeding-primary-care-interventions</a></p> <p>(October 2016)</p> <p>Grade: B</p>                 | <p>Maternity services:</p> <p>IC 10123.865</p> <p>IC 10123.866</p> <p>Comprehensive preventive care for children aged 16 years or younger:</p> <p>H&amp;SC 1367.35</p> <p>IC 10123.5</p> |
| 40 | Depression   | Counseling interventions (provision of or referral to) | Pregnant and postpartum persons who are at increased risk of perinatal depression |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p>   | <p>Perinatal Depression: Preventive Interventions</p> <p><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/perinatal-depression-preventive-interventions">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/perinatal-depression-preventive-interventions</a></p> <p>(February 2019)</p> <p>Grade: B</p> | <p>Maternity services:</p> <p>IC 10123.865</p> <p>IC 10123.866</p> <p>Maternal mental health:</p> <p>H&amp;SC 1367.625</p> <p>IC 10123.867</p>   |
| 41 | Gestational diabetes                                 | Screening  | Asymptomatic pregnant persons at or after 24 weeks gestation                      |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p>   | <p>Gestational Diabetes: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/gestational-diabetes-mellitus-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/gestational-diabetes-mellitus-screening</a></p> <p>(August 2021)</p> <p>Grade: B</p>                              | <p>Maternity services:</p> <p>IC 10123.865</p> <p>IC 10123.866</p> <p>Diabetes (including gestational):</p> <p>H&amp;SC 1367.51</p> <p>IC 10176.61</p>                                   |



| #  | Federal Mandates as Specified by Reference to USPSTF |                             |  |                                   |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>   |
|----|--|-----------------------------|--|-----------------------------------|---|---|---|
|    | Condition or Disease                                 | Test, Treatment, or Service | Specified Sex/Other <sup>23</sup>  | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>   |   |   |
| 42 | Hepatitis B virus (HBV) infection                    | Screening                   | Pregnant women   |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>At first prenatal visit</p> | <p>Hepatitis B Virus Infection in Pregnant Women: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-b-virus-infection-in-pregnant-women-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-b-virus-infection-in-pregnant-women-screening</a></p> <p>(July 2019)</p> <p>Grade: A</p> | <p>Maternity services:</p> <p>IC 10123.865</p> <p>IC 10123.866</p>  |
| 43 | Human immunodeficiency virus (HIV)                   | Screening                   | Pregnant persons - including those who present in labor or at delivery and whose HIV status is unknown |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p>                                | <p>Human Immunodeficiency Virus (HIV) Infection: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening</a></p> <p>(June 2019)</p> <p>Grade: A</p>                              | <p>Maternity services:</p> <p>IC 10123.865</p> <p>IC 10123.866</p> <p>HIV testing:</p> <p>H&amp;SC 1367.46</p> <p>IC 10123.91</p> |



| #  | Federal Mandates as Specified by Reference to USPSTF              |   |  |                                   |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup> |
|----|---|---|--|-----------------------------------|---|---|---|
|    | Condition or Disease  | Test, Treatment, or Service                               | Specified Sex/Other <sup>23</sup>                  | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>   |   |   |
| 44 | Neural tube defects<br>(Topic is in the process of being updated) | Folic acid supplementation to prevent neural tube defects | Women who are planning or are capable of pregnancy |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid</p> | <p>Folic Acid for the Prevention of Neural Tube Defects: Preventive Medication</p> <p><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication</a></p> <p>(January 2017)</p> <p>Grade: A</p> | <p>Maternity services:</p> <p>IC 10123.865</p> <p>IC 10123.866</p>                |
| 45 | Preeclampsia<br>(Topic is in the process of being updated)        | Screening with blood pressure measurements                | Pregnant women                                     |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Throughout pregnancy</p>  | <p>Preeclampsia: Screening</p> <p><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/preeclampsia-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/preeclampsia-screening</a></p> <p>(April 2017)</p> <p>Grade: B</p>   | <p>Maternity services:</p> <p>IC 10123.865</p> <p>IC 10123.866</p>                |

| #  | Federal Mandates as Specified by Reference to USPSTF |   |  |                                   |  | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup> |
|----|--|---|--|-----------------------------------|--|---|---|
|    | Condition or Disease                                 | Test, Treatment, or Service             | Specified Sex/Other <sup>23</sup>  | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>  |   |   |
| 46 | Preeclampsia   | Low-dose Aspirin (81 mg/d)              | Pregnant <u>persons</u> at high risk for preeclampsia, after 12 weeks gestation  |                                   | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i>  | Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication</a><br><br>(September 2021)<br><br>Grade: B | Maternity services:<br>IC 10123.865<br>IC 10123.866                               |
| 47 | Rh(D) incompatibility                                | Rh(D) blood typing and antibody testing | Pregnant women   |                                   | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i><br><br>During first visit for pregnancy-related care | Rh(D) Incompatibility: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/rh-d-incompatibility-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/rh-d-incompatibility-screening</a><br><br>(February 2004)<br><br>Grade: A  | Maternity services:<br>IC 10123.865<br>IC 10123.866                               |
| 48 | Rh(D) incompatibility                                | Repeated Rh(D) antibody testing         | Pregnant women who are unsensitized Rh(D)-negative at 24-28 weeks' gestation, unless the biological father is known to be Rh(D)-negative |                                   | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i>  | Rh(D) Incompatibility: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/rh-d-incompatibility-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/rh-d-incompatibility-screening</a><br><br>(February 2004)<br><br>Grade: B  | Maternity services:<br>IC 10123.865<br>IC 10123.866                               |

| #  | Federal Mandates as Specified by Reference to USPSTF |  |                                   |                                   |   | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup> |
|----|--|--|-----------------------------------|-----------------------------------|---|--|---|
|    | Condition or Disease                                 | Test, Treatment, or Service  | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup> | Terms <sup>25</sup>   |  |   |
| 49 | Syphilis infection                                   | Early screening  | Pregnant women                    |                                   | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Syphilis Infection in Pregnant Women: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/syphilis-infection-in-pregnancy-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/syphilis-infection-in-pregnancy-screening</a><br><br>(September 2018)<br><br>Grade: A   | Maternity services:<br><br>IC 10123.865<br><br>IC 10123.866                       |
| 50 | Tobacco use  | Ask about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation | Pregnant persons                  |                                   | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral Interventions<br><br><a href="https://www.uspreventiveservicestaskforce.org/uspsstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions">https://www.uspreventiveservicestaskforce.org/uspsstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions</a><br><br>(January 2021)<br><br>Grade: A | Maternity services:<br><br>IC 10123.865<br><br>IC 10123.866                       |



| #                    | Federal Mandates as Specified by Reference to USPSTF |                             |  |  |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>   |
|----------------------|--|-----------------------------|--|--|---|---|---|
|                      | Condition or Disease                                 | Test, Treatment, or Service | Specified Sex/Other <sup>23</sup>                        | Specified Age/Other <sup>24</sup>                              | Terms <sup>25</sup>   |   |   |
| <b>Sexual Health</b> |  |                             |  |  |   |   |   |
| 51                   | Chlamydial infection                                 | Screening                   | Sexually active women, <u>including pregnant persons</u> | 24 and younger and older women at increased risk for infection | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Chlamydia and Gonorrhea: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/chlamydia-and-gonorrhea-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/chlamydia-and-gonorrhea-screening</a><br><br>(September 2021)<br><br>Grade: B | Maternity services:<br>IC 10123.865<br>IC 10123.866<br><br>Comprehensive preventive care for children aged 16 years or younger:<br>H&SC 1367.35<br>IC 10123.5<br><br>Comprehensive preventive care for children aged 17 and 18 years:<br>H&SC 1367.3<br>IC 10123.55 |



| #  | Federal Mandates as Specified by Reference to USPSTF    |                             |  |   |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>   |
|----|---|-----------------------------|--|---|---|---|---|
|    | Condition or Disease                                    | Test, Treatment, or Service | Specified Sex/Other <sup>23</sup>                        | Specified Age/Other <sup>24</sup>                             | Terms <sup>25</sup>   |   |   |
| 52 | Gonorrhea<br>(Topic is in the process of being updated) | Screening                   | Sexually active women, <u>including pregnant persons</u> | 24 and younger and older women at increased risk of infection | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Chlamydia and Gonorrhea: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/chlamydia-and-gonorrhea-screening">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/chlamydia-and-gonorrhea-screening</a><br>(September 2021)<br><br>Grade: B | Maternity services:<br>IC 10123.865<br>IC 10123.866<br><br>Comprehensive preventive care for children aged 16 years or younger:<br>H&SC 1367.35<br>IC 10123.5<br><br>Comprehensive preventive care for children aged 17 and 18 years:<br>H&SC 1367.3<br>IC 10123.55 |



| #  | Federal Mandates as Specified by Reference to USPSTF                                 |   |                                   |   |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>   |
|----|--|---|-----------------------------------|---|---|---|---|
|    | Condition or Disease   | Test, Treatment, or Service   | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>               | Terms <sup>25</sup>   |   |   |
| 53 | Human immunodeficiency virus (HIV)<br><br>(Topic is in the process of being updated) | Pre-exposure prophylaxis (PrEP) with effective antiretroviral therapy |                                   | Persons who are at high risk of HIV acquisition | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis</a><br><br>(June 2019)<br><br>Grade: A | PrEP and Post-exposure prophylaxis (PEP) for prevention of HIV:<br><br>H&SC: 1342.74<br><br>IC 10123.1933<br><br>Combination antiretroviral drug treatments for prevention of HIV:<br><br>H&SC 1342.72<br><br>IC 10123.1931<br><br>Comprehensive preventive care for children aged 16 years or younger:<br><br>H&SC 1367.35<br><br>IC 10123.5<br><br>Comprehensive preventive care for children aged 17 and 18 years:<br><br>H&SC 1367.3<br><br>IC 10123.55 |



| #  | Federal Mandates as Specified by Reference to USPSTF |                                 |                                   |   |   | USPSTF A or B Recommendation <sup>21</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>  |
|----|--|---------------------------------|-----------------------------------|---|---|--|--|
|    | Condition or Disease                                 | Test, Treatment, or Service     | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>   | Terms <sup>25</sup>   |  |  |
| 54 | Human immunodeficiency virus (HIV)                   | Screening                       |                                   | Adolescents and adults aged 15 to 65 as well as younger and older persons at increased risk | <i>Without cost-sharing when in-network</i><br><i>As soon as 12 months after recommendation release</i> | Human Immunodeficiency Virus (HIV) Infection: Screening<br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening</a><br>(June 2019)<br>Grade: A    | HIV testing:<br>H&SC 1367.46<br>IC 10123.91<br>Comprehensive preventive care for children aged 17 and 18 years:<br>H&SC 1367.3<br>IC 10123.55  |
| 55 | Sexually transmitted infections (STIs)               | Intensive behavioral counseling |                                   | Sexually active adolescents and adults at increased risk for STIs                           | <i>Without cost-sharing when in-network</i><br><i>As soon as 12 months after recommendation release</i> | Sexually Transmitted Infections: Behavioral Counseling<br><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/sexually-transmitted-infections-behavioral-counseling">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/sexually-transmitted-infections-behavioral-counseling</a><br>(August 2020)<br>Grade: B | Comprehensive preventive care for children aged 16 years or younger:<br>H&SC 1367.35<br>IC 10123.5<br>Comprehensive preventive care for children aged 17 and 18 years:<br>H&SC 1367.3<br>IC 10123.55 |



| #  | Federal Mandates as Specified by Reference to USPSTF             |                             |                                   |  |   | USPSTF A or B Recommendation <sup>21</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>22</sup>  |
|----|--|-----------------------------|-----------------------------------|--|---|---|--|
|    | Condition or Disease   | Test, Treatment, or Service | Specified Sex/Other <sup>23</sup> | Specified Age/Other <sup>24</sup>                                  | Terms <sup>25</sup>   |   |  |
| 56 | Syphilis infection<br>(Topic is in the process of being updated) | Screening                   |                                   | Asymptomatic non-pregnant adolescents and adults at increased risk | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i> | Syphilis Infection in Nonpregnant Adults and Adolescents: Screening<br><br><a href="https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/syphilis-infection-in-nonpregnant-adults-and-adolescents">https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/syphilis-infection-in-nonpregnant-adults-and-adolescents</a><br><br>(June 2016)<br><br>Grade: A | Comprehensive preventive care for children aged 16 years or younger:<br><br>H&SC 1367.35<br><br>IC 10123.5<br><br>Comprehensive preventive care for children aged 17 and 18 years:<br><br>H&SC 1367.3<br><br>IC 10123.55 |



**Table 2. Federal Health Insurance Benefit Mandates as Specified by Reference to HRSA-Supported Health Plan Coverage Guidelines for Women’s Preventive Services<sup>28</sup> & Related Mandates in California State Law<sup>29,30</sup>**

| #   | Federal Mandates as Specified by Reference to HRSA-Supported Guidelines |                             |  |                                   |   | HRSA-Supported Health Plan Coverage Guidelines for Women’s Preventive Services <sup>31</sup>                         | Related Health Insurance Benefit Mandate(s) in California State Law <sup>32</sup> |
|---|---|-----------------------------|--|-----------------------------------|---|--|---|
|   | Condition or Disease  | Test, Treatment, or Service | Specified Sex/Other <sup>33</sup>  | Specified Age/Other <sup>34</sup> | Terms <sup>35</sup>   |  |   |
| HRSA-supported Health Plan Coverage Guidelines for Women’s Preventive Services were updated on 12/30/2021. In the rows that follow, recommendations released less than 12 months prior to 2/2/2022 are highlighted in the same color as this cell. If the new recommendation revises an older recommendation, the change is <u>underlined and defined</u> . |   |                             |  |                                   |   |  |   |
| 1   | Anxiety   | Screening                   | Adolescent and adult women, including those who are pregnant or postpartum |                                   | <i>Without cost-sharing when in-network</i><br><i>As soon as 12 months after recommendation release</i><br>Screening frequency up to clinical judgement | Screening for Anxiety<br><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a> | None identified   |

<sup>28</sup> Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act.

<sup>29</sup> For brevity, CHBRP has not listed in each row the California mandate (H&SC 1367.002 & IC 10112.2) that requires compliance with federal laws and regulations requiring coverage of preventive services without cost-sharing (Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act).

<sup>30</sup> CHBRP is aware that state regulation may require benefit coverage, but is focusing this resource on health insurance benefit mandate laws.

<sup>31</sup> Unless otherwise noted, the links listed below were accessed on or before 2/2/2022.

<sup>32</sup> Unless otherwise noted, the mandates listed below were reviewed on or before 2/2/2022.

<sup>33</sup> “Other” is included here in order to specify pregnant or non-pregnant women.

<sup>34</sup> “Other” is included here when more details are available about the intended group, beyond age.

<sup>35</sup> *Italicized terms* are explicit in the federal law (Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act). Non-italicized terms of benefit coverage are implied by the referenced recommendation.



| # | Federal Mandates as Specified by Reference to HRSA-Supported Guidelines |  |   |   |   | HRSA-Supported Health Plan Coverage Guidelines for Women’s Preventive Services <sup>31</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>32</sup>  |
|---|---|--|---|---|---|--|--|
|   | Condition or Disease  | Test, Treatment, or Service  | Specified Sex/Other <sup>33</sup>                                 | Specified Age/Other <sup>34</sup>                       | Terms <sup>35</sup>   |  |  |
| 2 | Breast Cancer   | Mammography  | Women at average risk of breast cancer                            | Initiate between ages 40 and 50 through at least age 74 | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>At least biennially and as frequently as annually</p> | <p>Breast Cancer Screening for Average-Risk Women</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p> | <p>Breast cancer screening, diagnosis, and treatment:</p> <p>H&amp;SC 1367.6</p> <p>IC 10123.8</p> <p>Cancer screening tests:</p> <p>H&amp;SC 1367.665</p> <p>IC 10123.20</p>            |
| 3 | Breastfeeding   | <p>Comprehensive lactation support services, including counseling, education, and breastfeeding equipment and supplies</p> <p><u>Breastfeeding equipment and supplies include double electric breast pumps, including pump parts and maintenance, and breast milk storage supplies</u></p> | Women, during the antenatal, perinatal, and the postpartum period |   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p>  | <p>Breastfeeding Services and Supplies</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p>            | <p>Maternity services:</p> <p>IC 10123.865</p> <p>IC 10123.866</p> <p>Comprehensive preventive care for children aged 16 years or younger:</p> <p>H&amp;SC 1367.35</p> <p>IC 10123.5</p> |



| # | Federal Mandates as Specified by Reference to HRSA-Supported Guidelines |                              |                                   |                                   |  | HRSA-Supported Health Plan Coverage Guidelines for Women’s Preventive Services <sup>31</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>32</sup>   |
|---|---|------------------------------|-----------------------------------|-----------------------------------|--|---|---|
|   | Condition or Disease  | Test, Treatment, or Service  | Specified Sex/Other <sup>33</sup> | Specified Age/Other <sup>34</sup> | Terms <sup>35</sup>  |   |   |
| 4 | Cervical Cancer   | Cervical cytology (Pap test) |                                   | 21 to 65                          | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Women 21 to 29 should be screened every 3 years</p> <p>Women 30 to 65 should be screened with cytology and HPV testing every 5 years, or cytology alone every 3 years</p> <p>Women with average risk should not be screened more than once every 3 years</p> | <p>Screening for Cervical Cancer</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p> | <p>Cancer screening tests:</p> <p>H&amp;SC 1367.665</p> <p>IC 10123.20</p> <p>Cervical cancer screening:</p> <p>H&amp;SC 1367.66</p> <p>IC 10123.18</p> |



| # | Federal Mandates as Specified by Reference to HRSA-Supported Guidelines |   |                                   |                                   |  | HRSA-Supported Health Plan Coverage Guidelines for Women’s Preventive Services <sup>31</sup>                            | Related Health Insurance Benefit Mandate(s) in California State Law <sup>32</sup>  |
|---|---|---|-----------------------------------|-----------------------------------|--|---|--|
|   | Condition or Disease  | Test, Treatment, or Service   | Specified Sex/Other <sup>33</sup> | Specified Age/Other <sup>34</sup> | Terms <sup>35</sup>  |   |  |
| 5 | Contraception   | <p>Full range of Food and Drug Administration (FDA)-approved, -granted, or -cleared contraceptive methods, effective family planning practices, and sterilization procedures</p> <p><u>Contraceptive care includes screening, education, counseling, provision of contraceptives, and follow-up care</u></p> <p>NOTE: Exemptions for religious employers or employers with moral objections may be granted by HRSA<sup>36</sup></p> | Adolescent and adult women        |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> | <p>Contraception</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p> | <p>Contraceptive devices requiring a prescription:</p> <p>H&amp;SC 1367.25</p> <p>IC 10123.196</p> <p>Reproductive health care services:</p> <p>H&amp;SC 1367.31</p> <p>IC 10123.202</p> |

<sup>36</sup> See Federal Register /Vol. 82, No. 221 /Thursday, November 15, 2018 /Rules and Regulations available at: <https://www.govinfo.gov/content/pkg/FR-2018-11-15/pdf/2018-24512.pdf> and Federal Register /Vol. 83, No. 221 /Thursday, November 15, 2018 /Rules and Regulations available at: <https://www.govinfo.gov/content/pkg/FR-2018-11-15/pdf/2018-24514.pdf>. On July 8, 2020, the Supreme Court upheld these final rules in *Little Sisters of the Poor v. Pennsylvania*, 591 U. S. \_\_\_\_ (2020).

| # | Federal Mandates as Specified by Reference to HRSA-Supported Guidelines |  |   |                                   |  | HRSA-Supported Health Plan Coverage Guidelines for Women’s Preventive Services <sup>31</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>32</sup>  |
|---|---|--|---|-----------------------------------|--|--|--|
|   | Condition or Disease  | Test, Treatment, or Service              | Specified Sex/Other <sup>33</sup>   | Specified Age/Other <sup>34</sup> | Terms <sup>35</sup>  |  |  |
| 6 | Diabetes  | Screening                                | Postpartum women with a history of gestational diabetes and who have not been previously diagnosed with type 2 diabetes |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Should occur within the first year and as early as 4-6 weeks postpartum</p> <p>Women with negative tests should be rescreened at least every 3 years for a minimum of 10 years after pregnancy</p> | <p>Screening for Diabetes Mellitus after Pregnancy</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p>      | <p>Diabetes (including gestational):</p> <p>H&amp;SC 1367.51</p> <p>IC 10176.61</p>  |
| 7 | Gestational diabetes  | Screening                                | Pregnant women, between 24 and 28 weeks of gestation (or at first prenatal visit for women at high risk for diabetes)   |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p>   | <p>Screening for Gestational Diabetes Mellitus</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p>          | <p>Maternity services:</p> <p>IC 10123.865</p> <p>IC 10123.866</p> <p>Diabetes (including gestational):</p> <p>H&amp;SC 1367.51</p> <p>IC 10176.61</p> |
| 8 | Human immunodeficiency virus (HIV)                                      | Prevention education and risk assessment | Adolescent and adult women  |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Annually</p>   | <p>Screening for Human Immunodeficiency Virus Infection</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p> | <p>HIV testing:</p> <p>H&amp;SC 1367.46</p> <p>IC 10123.91</p>   |



| #  | Federal Mandates as Specified by Reference to HRSA-Supported Guidelines |  |   |   |  | HRSA-Supported Health Plan Coverage Guidelines for Women’s Preventive Services <sup>31</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>32</sup> |
|----|---|--|---|---|--|--|---|
|    | Condition or Disease  | Test, Treatment, or Service  | Specified Sex/Other <sup>33</sup>   | Specified Age/Other <sup>34</sup>   | Terms <sup>35</sup>  |  |   |
| 9  | Human immunodeficiency virus (HIV)                                      | Screening  | Adolescent and adult women, women with an increased risk of HIV infection, pregnant women | <u>15 and older</u>   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>All women should be tested for HIV at least once during their lifetime</p> <p>Screening annually or more often may be appropriate <u>beginning at age 13</u> for women with an increased risk of HIV infection</p> <p>All pregnant women upon initiation of prenatal care with retesting based on risk factors</p> | <p>Screening for Human Immunodeficiency Virus Infection</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p> | <p>HIV testing:</p> <p>H&amp;SC 1367.46</p> <p>IC 10123.91</p>                    |
| 10 | Interpersonal and domestic violence                                     | Screening and, when needed, providing or referring for initial intervention services | Adolescent and adult women  |   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>At least annually</p>  | <p>Screening for Interpersonal and Domestic Violence</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p>    | None identified   |
| 11 | Obesity   | Counseling   | Midlife women   | 40 to 60 years with normal or overweight body mass index (BMI) (18.5-29.9 kg/m <sup>2</sup> ) | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p>   | <p>Obesity Prevention in Midlife Women</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p>                  | None identified   |



| #  | Federal Mandates as Specified by Reference to HRSA-Supported Guidelines |                             |  |                                   |  | HRSA-Supported Health Plan Coverage Guidelines for Women’s Preventive Services <sup>31</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>32</sup> |
|----|---|-----------------------------|--|-----------------------------------|--|--|---|
|    | Condition or Disease  | Test, Treatment, or Service | Specified Sex/Other <sup>33</sup>  | Specified Age/Other <sup>34</sup> | Terms <sup>35</sup>  |  |   |
| 12 | Sexually transmitted infections (STIs)                                  | Counseling                  | Adolescent and adult women who are sexually active and at an increased risk for STIs |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Directed behavioral counseling by a health care provider or other appropriately trained individual</p> | <p>Counseling for Sexually Transmitted Infections</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p> | None identified   |
| 13 | Urinary Incontinence  | Screening                   | Women  |                                   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Annually</p> <p>Women should be referred for further evaluation and treatment if indicated</p>         | <p>Screening for Urinary Incontinence</p> <p><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a></p>             | None identified   |



| #  | Federal Mandates as Specified by Reference to HRSA-Supported Guidelines |   |                                   |                                   |  | HRSA-Supported Health Plan Coverage Guidelines for Women’s Preventive Services <sup>31</sup>                                    | Related Health Insurance Benefit Mandate(s) in California State Law <sup>32</sup>   |
|----|---|---|-----------------------------------|-----------------------------------|--|---|---|
|    | Condition or Disease  | Test, Treatment, or Service   | Specified Sex/Other <sup>33</sup> | Specified Age/Other <sup>34</sup> | Terms <sup>35</sup>  |   |   |
| 14 | Wellness  | Well-woman preventive care visit(s), <u>completed at a single or as part of a series of visits that take place over time, depending on age, health status, reproductive health needs, pregnancy status, and risk factors</u><br><br><u>Well-women visits include pre-pregnancy, prenatal, postpartum, and interpregnancy visits</u> | Adolescent and adult women        |                                   | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i><br><br>At least one preventive care visit per year beginning in adolescence and continuing across the lifespan as determined by age and risk factors | Well-Woman Preventive Visits<br><br><a href="https://www.hrsa.gov/womens-guidelines">https://www.hrsa.gov/womens-guidelines</a> | Multiple mandates relate. See specific conditions or disorders.<br><br>Any related health insurance benefit mandate in California state law in this document that relates to women. |



**Table 3. Federal Health Insurance Benefit Mandates as Specified by Reference to HRSA-Supported Comprehensive Guidelines for Infants, Children, and Adolescents<sup>37</sup> & Related Mandates in California State Law<sup>38,39</sup>**

| #   | Federal Mandates as Specified by Reference to HRSA-Supported Guidelines |   |                     |  |  | HRSA-Supported Comprehensive Guidelines for Infants, Children, and Adolescents <sup>40</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>41</sup>  |
|---|---|---|---------------------|--|--|--|--|
|   | Condition or Disease  | Test, Treatment, or Service   | Specified Sex/Other | Specified Age/Other  | Terms <sup>42</sup>  |  |  |
| In the rows that follow, recommendations released less than 12 months prior to 2/2/2022 are highlighted in the same color as this cell. |   |   |                     |  |  |  |  |
| 1   | Wellness  | Screening (many, which includes autism screening)—for full list, see <i>Bright Futures</i> schedule (see link in this row, next to last column) |                     | 21 and younger, with varied ages for varied screenings – for full list, see <i>Bright Futures</i> schedule (see link in this row, next to last column) | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Health benefit coverage requirements vary by screening and also vary by age— for full list, see <i>Bright Futures</i> schedule (see link in this row, next to last column)</p> | <p>Recommendations for Preventive Pediatric Health Care</p> <p>Bright Futures/ American Academy of Pediatrics</p> <p><a href="https://www.aap.org/en-us/Documents/periodicity_schedule.pdf">https://www.aap.org/en-us/Documents/periodicity_schedule.pdf</a></p> <p>(March 2021)</p> | <p>Comprehensive preventive care for children aged 16 years or younger:<sup>43</sup></p> <p>H&amp;SC 1367.35</p> <p>IC 10123.5</p> <p>Comprehensive preventive care for children aged 17 and 18 years:</p> <p>H&amp;SC 1367.3</p> <p>IC 10123.55</p> |

<sup>37</sup> Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act.

<sup>38</sup> For brevity, CHBRP has not listed in each row the California mandate (H&SC 1367.002 & IC 10112.2) that requires compliance with federal laws and regulations requiring coverage of preventive services without cost-sharing (Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act).

<sup>39</sup> CHBRP is aware that state regulation may require benefit coverage, but is focusing this resource on health insurance benefit mandate laws.

<sup>40</sup> Unless otherwise noted, the links listed below were accessed on or before 2/2/2022.

<sup>41</sup> Unless otherwise noted, the mandates listed below were reviewed on or before 2/2/2022.

<sup>42</sup> *Italicized terms* are explicit in the federal law (Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act). Non-italicized terms of benefit coverage are implied by the referenced recommendation.

<sup>43</sup> This statute references a similar but older (1987) set of American Academy of Pediatrics recommendations.



| # | Federal Mandates as Specified by Reference to HRSA-Supported Guidelines |   |                     |  |  | HRSA-Supported Comprehensive Guidelines for Infants, Children, and Adolescents <sup>40</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>41</sup>  |
|---|---|---|---------------------|--|--|---|--|
|   | Condition or Disease  | Test, Treatment, or Service   | Specified Sex/Other | Specified Age/Other  | Terms <sup>42</sup>  |   |  |
| 2 | Wellness  | Screening (many)—for full list, see Heritable Disorders panel (see link in this row, next to last column) |                     | Newborns and children – for full list, see Heritable Disorders panel (see link in this row, next to last column) | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> | <p>Recommended Uniform Screening Panel of the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children</p> <p><a href="https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/rusp-uniform-screening-panel.pdf">https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/rusp-uniform-screening-panel.pdf</a></p> <p>(Includes recommendations in effect as of July 2018)</p> | <p>Maternity services:</p> <p>IC 10123.865</p> <p>IC 10123.866</p> <p>Comprehensive preventive care for children aged 16 years or younger:</p> <p>H&amp;SC 1367.35</p> <p>IC 10123.542</p> |

**Table 4. Federal Health Insurance Benefit Mandates as Specified by ACIP Recommendations<sup>44,45</sup>**

| #  | Federal Mandates as Specified by Reference to ACIP Recommendations |   |                     |  |   | ACIP Recommendations <sup>46</sup>  | Related Health Insurance Benefit Mandate(s) in California State Law <sup>47</sup>   |
|--|--|---|---------------------|--|---|---|---|
|  | Condition or Disease   | Test, Treatment, or Service   | Specified Sex/Other | Specified Age/Other  | Terms <sup>48</sup>   |   |   |
| In the rows that follow, recommendations released less than 12 months prior to 1/26/2022 are highlighted in the same color as this cell. |  |   |                     |  |   |   |   |
| 1  | Vaccine preventable diseases                                       | Immunizations (many) – for the full list, see the ACIP schedule (see link in this row, next to last column) |                     | 0 through 18 years, with varied ages for varied immunizations – for the full list, see ACIP schedule (see link in this row, next to last column) | <i>Without cost-sharing when in-network</i><br><br><i>As soon as 12 months after recommendation release</i><br><br>Immunization coverage requirements vary by vaccine and also vary by age – for the full list, see ACIP schedule (see link in this row, next to last column) | Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger— United States, 2020 (Table 1)<br><br><a href="https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf">https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf</a><br><br>(Includes recommendations in effect as of February 11, 2021) | Maternity services:<br>IC 10123.865<br>IC 10123.866<br><br>Comprehensive preventive care for children aged 16 years or younger:<br>H&SC 1367.35<br>IC 10123.5<br><br>Comprehensive preventive care for children aged 17 and 18 years:<br>H&SC 1367.3<br>IC 10123.55 |

<sup>44</sup> For brevity, CHBRP has not listed in each row the California mandate (H&SC 1367.002 & IC 10112.2) that requires compliance with federal laws and regulations requiring coverage of preventive services without cost-sharing (Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act).

<sup>45</sup> CHBRP is aware that state regulation may require benefit coverage, but is focusing this resource on health insurance benefit mandate laws.

<sup>46</sup> Unless otherwise noted, the links listed below were accessed on or before 2/2/2022.

<sup>47</sup> Unless otherwise noted, the mandates listed below were reviewed on or before 2/2/2022.

<sup>48</sup> *Italicized terms* are explicit in the federal law (Affordable Care Act Section 1001, modifying Section 2713 of the Public Health Service Act). Non-italicized terms of benefit coverage are implied by the referenced recommendation.



| # | Federal Mandates as Specified by Reference to ACIP Recommendations |  |                     |   |  | ACIP Recommendations <sup>46</sup>   | Related Health Insurance Benefit Mandate(s) in California State Law <sup>47</sup>   |
|---|--|--|---------------------|---|--|--|---|
|   | Condition or Disease   | Test, Treatment, or Service  | Specified Sex/Other | Specified Age/Other   | Terms <sup>48</sup>  |  |   |
| 2 | Vaccine preventable diseases                                       | Catch-up immunizations (many) – for the full list, see the ACIP schedule (see link in this row, next to last column) |                     | 4 months through 18 years, who start late or who are more than 1 month behind, with varied ages for varied immunizations – for the full list, see ACIP schedule (see link in this row, next to last column) | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Immunization coverage requirements vary by vaccine and also vary by age – for the full list, see ACIP schedule (see link in this row, next to last column)</p> | <p>Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who are More than 1 month Behind—United States, 2020 (Table 2)</p> <p><a href="https://www.cdc.gov/vaccines/schedules/download/s/child/0-18yrs-child-combined-schedule.pdf">https://www.cdc.gov/vaccines/schedules/download/s/child/0-18yrs-child-combined-schedule.pdf</a></p> <p>(Includes recommendations in effect as of February 11, 2021)</p> | <p>Comprehensive preventive care for children aged 16 years or younger:</p> <p>H&amp;SC 1367.35</p> <p>IC 10123.5</p> <p>Comprehensive preventive care for children aged 17 and 18 years:</p> <p>H&amp;SC 1367.3</p> <p>IC 10123.55</p> |
| 3 | Vaccine preventable diseases                                       | Immunizations (many) – for the full list, see the ACIP schedule (see link in this row, next to last column)          |                     | Adults 19 and older, with varied ages for varied immunizations – for the full list, see ACIP schedule (see link in this row, next to last column)   | <p><i>Without cost-sharing when in-network</i></p> <p><i>As soon as 12 months after recommendation release</i></p> <p>Immunization coverage requirements vary by vaccine and also vary by age – for the full list, see ACIP schedule (see link in this row, next to last column)</p> | <p>Recommended Adult Immunization Schedule for ages 19 years or older—United States, 2020</p> <p><a href="https://www.cdc.gov/vaccines/schedules/download/s/adult/adult-combined-schedule.pdf">https://www.cdc.gov/vaccines/schedules/download/s/adult/adult-combined-schedule.pdf</a></p> <p>(Includes recommendations in effect as of February 11, 2021)</p>   | None identified   |

## ABOUT CHBRP

The California Health Benefits Review Program (CHBRP) was established in 2002. As per its authorizing statute, CHBRP provides the California Legislature with independent analysis of the medical, financial, and public health impacts of proposed health insurance benefit-related legislation. The state funds CHBRP through an annual assessment on health plans and insurers in California.

Detailed information on CHBRP's analysis methodology, authorizing statute, as well as all CHBRP analyses and other publications are available at <http://www.chbrp.org/>.

### CHBRP Staff

**Garen Corbett, MS**, Director  
**John Lewis, MPA**, Associate Director  
**Adara Citron, MPH**, Principal Policy Analyst  
**Sabrina Woll**, Policy Associate  
**Karen Shore, PhD**, Contractor\*  
**An-Chi Tsou, PhD**, Contractor\*

**California Health Benefits Review Program**  
**MC 3116**  
**Berkeley, CA 94720-3116**  
[info@chbrp.org](mailto:info@chbrp.org)  
[www.chbrp.org](http://www.chbrp.org)  
(510) 664-5306

\*Karen Shore, PhD, and An-Chi Tsou, PhD, are Independent Contractors who work with CHBRP to support legislative analyses and other special projects on a contractual basis.

CHBRP is an independent program administered and housed by the University of California, Berkeley, in the Office of the Vice Chancellor for Research.

CHBRP assumes full responsibility for the resource and the accuracy of its contents.